Chronic Hepatitis B, Hepatitis B
Conditions
Keywords
hepatitis B, Toll-like receptor, vaccine, hepatitis B surface antibody, HBsAb, anti-HBsAg, hepatitis B surface antigen, HBsAg, TLR9, CpG
Brief summary
The goal of this clinical trial is to learn if HEPLISAV-B, a vaccine that is approved to prevent hepatitis B infection in people that are not already infected, is safe in people already chronically infected with hepatitis B. The main quiestions it aims to answer are: 1. Is HEPLISAV-B safe in people with chronic hepatitis B? 2. What side effects, if any, could HEPLISAV-B cause in people with chronic hepatitis B? 3. How does HEPLISAV-B affect the cells that fight chronic hepatitis B? Participants will: * Receive HEPLISAV-B as an injection in the muscle, one injection every 4 weeks, for a total of 2 injections. * Visit the clinic a total of 5 times, and have 3 phone follow ups over 14 months. * Be asked if they are having any side effects from HEPLISAV-B. * Have blood samples collected.
Detailed description
Ten people with chronic hepatitis B and virally suppressed on nucleos(t)ide analogue (NUC) therapy will receive a total of two 0.5ml intramuscular injections of HEPLISAV-B, a CpG-adjuvanted vaccine, the first injection on day 0, and the second injection on week 4. Participants will visit the clinic on day 0, and weeks 2, 4, 8, and 28. They will also have phone follow ups on day 7, and weeks 5 and 56. At each follow up, participants will be asked about any side effects. At each clinic visit blood samples will be collected. For 7 days after each HEPLISAV-B injection, participants will complete a diary to document any reactions to the injection.
Interventions
DRUGHepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
one 0.5ml intramuscular injection on day 0 and week 4.
Sponsors
University of Maryland, Baltimore
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
In order to participate in this study, an individual must meet all the following criteria: 1. \>18 years old 2. Diagnosed with CHB infection, without HIV, hepatitis C nor hepatitis D co-infections 3. Currently receiving NUC with HBV VL \<100 IU/ml for ≥ 12 months 4. Willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, and other study procedures. 5. Determined by medical history, targeted physical examination, and clinical judgement of the investigator to be in good health. CHB infection is defined as any individual with documentation of a positive HBsAg and/or detectable HBV DNA test for at least 6 months.
Exclusion criteria
A participant will be ineligible to participate on this study if any of the following criteria are met: 1. Pregnancy or breast feeding. 2. Received systemic immunosuppressants or immune-modifying drugs for \>14 days in total within 6 months prior to Screening (for corticosteroids ≥ 20 mg/day of prednisone equivalent). Received anti-CD20 immunosuppressant within 12 months of screening. Topical tacrolimus is allowed if not used within 14 days prior to Day 1. 3. Received or plans to receive live virus vaccines within 4 weeks, and inactivated vaccine within 2 weeks prior to randomization; or plans to receive a non-study vaccine within 28 days after any dose of study vaccine (with exception for seasonal influenza vaccine within 14 days of study vaccine). 4. Administration of any blood products within 3 months prior to randomization. 5. Participation in a study with an investigational study product or device within 30 days of randomization. 6. Has allergies to any hepatitis B and/or yeast-based vaccines. 7. Subjects meeting any of the following laboratory parameters at screening: 1. ALT greater than 3 times the upper limit of normal 2. Elevated total bilirubin WITH direct bilirubin greater than 2 times upper limit of normal 8. Is acutely ill or febrile 72 hours prior to or at vaccine dosing (fever defined as ≥ 38.0°C/100.4°F). Participants meeting this criterion may be rescheduled within the relevant window periods. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. 9. Have any chronic or acute or unstable conditions that the investigator considers a contraindication to study participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and reactogenicity of the Hepatitis B Virus Surface Antigen, Recombinant (HEPLISAV-B; Dynavax Technologies Corporation) Vaccine in patients with chronic hepatitis B | Baseline to 7 days following each vaccine dose | Number of local and systemic solicited adverse events |
| Occurence of unsolicited adverse events | from dose 1 to 28 days following each vaccine dose | Number of unsolicited adverse events |
| Medically Attended Adverse Events | From first vaccine to 12 months after last vaccine on study. | Number of Medically Attended Adverse Events (MAAEs) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in hepatitis B surface antigen levels | Day 0 to week 28 | Hepatitis B surface antigen levels (international units per milliliter, IU/mL) will be measured at baseline, and thoughout study |
| Anti-HBsAg Seroconversion | Day 0 through 12 months post vaccination | Number of patients with anti-HBsAg seroconversion |
| Changes in immunologic and virologic responses throughout study | baseline to week 28 | Change in hepatitis B surface antigen-specific immune cell types (percentage of cells) and function (percentage of cells producing cytokines), and hepatitis B virus viral markers (international units per milliliter, IU/mL) will be evaluated at baseline, and throughout the study. |
Countries
United States
Contacts
Primary ContactLydia Tang, MBChB
Outcome results
None listed